Results 291 to 300 of about 319,530 (379)

Nutritional priorities to support GLP‐1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society

open access: yesObesity, EarlyView.
Abstract Background Glucagon‐like peptide 1 receptor agonists and combination medications (hereafter collectively referred to as GLP‐1s) are shifting the treatment landscape for obesity. However, real‐world challenges and limited clinician and public knowledge on nutritional and lifestyle interventions can limit GLP‐1 efficacy, equitable results, and ...
Dariush Mozaffarian   +17 more
wiley   +1 more source

Effect of Polypropylene‐Grafted‐Maleic Anhydride and Rice Husk Particle Size on 3D‐Printing Filament Composites From Recycled Polypropylene

open access: yesPolymer Composites, EarlyView.
Development of 3D printing composite filaments from recycled polypropylene and agro‐industrial residues: blending, extrusion, and mechanical validation. ABSTRACT This study evaluates the combined roles of particle size and the addition of maleic anhydride polypropylene (PP‐g‐MAH) to improve 3D printing and mechanical properties of composite filaments ...
Maria A. Morales   +6 more
wiley   +1 more source

Differential Effect of Omega-3 Fatty Acids on Platelet Inhibition by Antiplatelet Drugs In Vitro. [PDF]

open access: yesInt J Mol Sci
Koutsaliaris IK   +5 more
europepmc   +1 more source

Tissue‐Specific Regulation of Fatty Acid Metabolism in a Mouse Model of Isolated Complex I Deficiency

open access: yesPROTEOMICS, EarlyView.
ABSTRACT Isolated complex I deficiency (ICD) is commonly associated with mitochondrial diseases and closely mimics subacute necrotising encephalomyelopathy. This disorder is characterised by metabolic perturbations that affect energy metabolism pathways, including fatty acid metabolism.
Sibonelo Glen Khumalo   +2 more
wiley   +1 more source

Model‐Based Meta‐Analysis of the Relationship Between Pioglitazone and Histological Outcomes in Metabolic Dysfunction‐Associated Steatohepatitis Patients

open access: yesCPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Given the high prevalence of the population who have metabolic dysfunction‐associated steatohepatitis (MASH), interest is growing in MASH‐targeted treatments. However, currently, there has been only one regulatory approved drug for MASH (Rezdiffra).
Quyen Thi Tran   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy